<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557943</url>
  </required_header>
  <id_info>
    <org_study_id>2708201904</org_study_id>
    <nct_id>NCT04557943</nct_id>
  </id_info>
  <brief_title>Prolotherapy Intervention Effect in Patient With Knee Osteoarthritis</brief_title>
  <official_title>The Level of Cartilage Oligomeric Matrix Protein (COMP) and Urinary C-Terminal Telopeptides of Type II Collagen (uCTX-II) After Prolotherapy Intervention and The Functional Outcome in Patient With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasanuddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasanuddin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction :&#xD;
&#xD;
      Prolotherapy is regenerative tissue therapy which is considered to be efficacious in reducing&#xD;
      symptoms and morbidity of Knee Osteoarthritis (KOA), but only a few studies demonstrate the&#xD;
      effect of prolotherapy at the biomolecular level, particularly the level of Cartilage&#xD;
      Oligomeric Matrix Protein (COMP), and Urinary C-Terminal Telopeptides of Type II Collagen&#xD;
      (uCTX-II) as the biomarkers of cartilage repair.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To determine the effect of prolotherapy on COMP and uCTX-II levels, and functional outcomes&#xD;
      in KOA patients.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      a double-blind randomized controlled trial study involving 36 participants who had been&#xD;
      diagnosed with KOA. History taking, functional outcome assessment, COMP, and uCTX-II were&#xD;
      measured. The prolotherapy via intraarticular and extraarticular was performed at Day-1,&#xD;
      Day-29, and Day-57 followed by the evaluation of functional outcome, COMP, and uCTX-II at day&#xD;
      78&#xD;
&#xD;
      Alternative Hypothesis :&#xD;
&#xD;
      Prolotherapy provides improvement of cartilage based on COMP and UCTX-II levels and&#xD;
      functional outcome among KOA patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design :&#xD;
&#xD;
      Double-blind randomized trial&#xD;
&#xD;
      Randomization :&#xD;
&#xD;
      Simple Randomization generated by an online randomizer&#xD;
&#xD;
      Sample Size :&#xD;
&#xD;
      Difference between two means of primary outcome where&#xD;
&#xD;
        1. mean difference (μ 1 - μ 2 ) = 0.05&#xD;
&#xD;
        2. pool variance = 0.09&#xD;
&#xD;
        3. Z 1-α/2 = 1.95 with type 1 error 5%&#xD;
&#xD;
        4. 1-β = 1.282 with power 90%. Yielding 16 patients for each arm&#xD;
&#xD;
      Time Period of Recruitment September 2019- August 2020&#xD;
&#xD;
      Detailed Intervention&#xD;
&#xD;
        1. Intervention group : Prolotherapy given three times (Day-1, Day-29, and Day-57 )&#xD;
&#xD;
        2. Comparison group : Hyaluronate given five times (Day-1, Day-8, Day-15, Day-22, and&#xD;
           Day-29.)&#xD;
&#xD;
      Outcome Measurement :&#xD;
&#xD;
        1. Cartilage Oligomeric Matrix Protein (COMP) Source of Sample : Median Cubital Vein Whole&#xD;
           Blood Measurement : Enzyme-linked Immunoassay&#xD;
&#xD;
        2. Urinary C-Terminal Telopeptides of Type II Collagen (uCTX-II) Source of Sample : 50 cc&#xD;
           of random urine sample Measurement : Enzyme-linked Immunoassay&#xD;
&#xD;
        3. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for functional&#xD;
           Outcome (self-reported assessment)&#xD;
&#xD;
      Domains :&#xD;
&#xD;
        1. five elements of pain (score range 0-20),&#xD;
&#xD;
        2. two for stiffness (score range 0-8),&#xD;
&#xD;
        3. 17 for functional limitation (score range 0-68)&#xD;
&#xD;
      Classification :&#xD;
&#xD;
      0 - 24 : Mild 25 - 48 : Moderate 49 - 72 : Severe 73 - 96 : Extremely Severe&#xD;
&#xD;
      Statistical analysis :&#xD;
&#xD;
        1. Descriptive statistic to elaborate baseline characteristic&#xD;
&#xD;
        2. Assuming the baseline characteristic between groups are similar, the independent t-test&#xD;
           will be conducted to see the differences between group, whereas Mann Whitney will be&#xD;
           performed for non parametric data&#xD;
&#xD;
        3. Difference within group (baseline and last day) will be measured by paired-t test or&#xD;
           wilcoxon for non parametric scenario&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study involves two arms assigned randomly for receiving different treatment. One arm for Prolotherapy and Sodium Hyaluronate in the comparison group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>A sealed envelope of the randomized sequence was given to the investigator and care provider, and participants were recruited consecutively according to the sequence. Participants were masked from the therapy by receiving treatment individually in different rooms and occasions. On the day of the assessment, the physician and laboratory technicians were blinded from group allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cartilage Oligomeric Matrix Protein (COMP)</measure>
    <time_frame>Measured on the first day before intervention and day 78 after the first dose of treatment in all groups</time_frame>
    <description>cartilage oligomeric matrix protein from whole blood measured using Enzyme-linked Immunoassay (ELISA). Mean difference between group will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary C-Terminal Telopeptides of Type II Collagen (uCTX-II)</measure>
    <time_frame>Measured on the first day before intervention and day 78 after the first injection on the prolotherapy group and Day 50 after the first injection for the hyaluronate group</time_frame>
    <description>Urinary C-Terminal Telopeptides of Type II Collagen from urine sample measured using Enzyme-linked Immunoassay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome</measure>
    <time_frame>Measured on the first day before intervention and day 78 after the first injection on the prolotherapy group and Day 50 after the first injection for the hyaluronate group</time_frame>
    <description>the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index ) measuring three domains (pain, function limitation and stiffness) ranging from 0-96 of total score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:&#xD;
in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolotherapy</intervention_name>
    <description>Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:&#xD;
in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th.</description>
    <arm_group_label>Prolotherapy</arm_group_label>
    <other_name>Prolotherapy Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th</description>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <other_name>2 mL Sodium Hyaluronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient provides consent to be part of the research.&#xD;
&#xD;
          2. The diagnosis of Knee Osteoarthritis was made based on clinical criteria/radiology&#xD;
             American College of Rheumatology (ACR) 2012 with radiology grading according to&#xD;
             Kellgren-Lawrence 2-3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The Patient has received other forms of intraarticular injection therapy.&#xD;
&#xD;
          2. The patient has received Non Steroid Anti inflammation drug (NSAID) therapy for one&#xD;
             week before the start of the intervention.&#xD;
&#xD;
          3. The patient has one or more contraindications for prolotherapy (e.g., Abscess,&#xD;
             cellulitis, or septic arthritis).&#xD;
&#xD;
        Drop Out Criteria :&#xD;
&#xD;
          1. The patient has undergone a strenuous physical activity that precipitates a degree of&#xD;
             complication (i.e., joint effusion).&#xD;
&#xD;
          2. The use of NSAID within one week after the intervention.&#xD;
&#xD;
          3. The patient does not adhere to the intervention.&#xD;
&#xD;
          4. The patient developed or being diagnosed with osteoarthritis or other forms of&#xD;
             inflammatory disease in other joints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yose Waluyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hasanuddin University, Faculty of Medicine</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>90245</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Rabago D, Zgierska A, Fortney L, Kijowski R, Mundt M, Ryan M, Grettie J, Patterson JJ. Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: results of a single-arm uncontrolled study with 1-year follow-up. J Altern Complement Med. 2012 Apr;18(4):408-14. doi: 10.1089/acm.2011.0030.</citation>
    <PMID>22515800</PMID>
  </reference>
  <reference>
    <citation>Eslamian F, Amouzandeh B. Therapeutic effects of prolotherapy with intra-articular dextrose injection in patients with moderate knee osteoarthritis: a single-arm study with 6 months follow up. Ther Adv Musculoskelet Dis. 2015 Apr;7(2):35-44. doi: 10.1177/1759720X14566618.</citation>
    <PMID>25829954</PMID>
  </reference>
  <reference>
    <citation>Rabago D, Patterson JJ, Mundt M, Kijowski R, Grettie J, Segal NA, Zgierska A. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2013 May-Jun;11(3):229-37. doi: 10.1370/afm.1504. Erratum in: Ann Fam Med. 2013 Sep-Oct;11(5):480.</citation>
    <PMID>23690322</PMID>
  </reference>
  <reference>
    <citation>Arias-Vázquez PI, Tovilla-Zárate CA, Legorreta-Ramírez BG, Burad Fonz W, Magaña-Ricardez D, González-Castro TB, Juárez-Rojop IE, López-Narváez ML. Prolotherapy for knee osteoarthritis using hypertonic dextrose vs other interventional treatments: systematic review of clinical trials. Adv Rheumatol. 2019 Aug 19;59(1):39. doi: 10.1186/s42358-019-0083-7.</citation>
    <PMID>31426856</PMID>
  </reference>
  <reference>
    <citation>Scarpellini M, Lurati A, Vignati G, Marrazza MG, Telese F, Re K, Bellistri A. Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the &quot;Magenta osteoarthritis study&quot;. J Orthop Traumatol. 2008 Jun;9(2):81-7. doi: 10.1007/s10195-008-0007-5. Epub 2008 May 28.</citation>
    <PMID>19384621</PMID>
  </reference>
  <reference>
    <citation>Garnero P, Conrozier T, Christgau S, Mathieu P, Delmas PD, Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis. 2003 Oct;62(10):939-43.</citation>
    <PMID>12972471</PMID>
  </reference>
  <reference>
    <citation>Huang M, Zhao J, Huang Y, Dai L, Zhang X. Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis. J Orthop Translat. 2017 Aug 15;13:50-57. doi: 10.1016/j.jot.2017.06.005. eCollection 2018 Apr.</citation>
    <PMID>29662791</PMID>
  </reference>
  <reference>
    <citation>Hoch JM, Mattacola CG, Medina McKeon JM, Howard JS, Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2011 Dec;19(12):1396-404. doi: 10.1016/j.joca.2011.09.005. Epub 2011 Oct 5. Review.</citation>
    <PMID>22001901</PMID>
  </reference>
  <reference>
    <citation>Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res. 2013 Jul;31(7):999-1006. doi: 10.1002/jor.22324. Epub 2013 Feb 19.</citation>
    <PMID>23423905</PMID>
  </reference>
  <reference>
    <citation>Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, Martin BC. Comparison of Low-, Moderate-, and High-Molecular-Weight Hyaluronic Acid Injections in Delaying Time to Knee Surgery. J Arthroplasty. 2017 Oct;32(10):2952-2957.e21. doi: 10.1016/j.arth.2017.04.041. Epub 2017 May 2.</citation>
    <PMID>28606459</PMID>
  </reference>
  <reference>
    <citation>Topol GA, Podesta LA, Reeves KD, Giraldo MM, Johnson LL, Grasso R, Jamín A, Clark T, Rabago D. Chondrogenic Effect of Intra-articular Hypertonic-Dextrose (Prolotherapy) in Severe Knee Osteoarthritis. PM R. 2016 Nov;8(11):1072-1082. doi: 10.1016/j.pmrj.2016.03.008. Epub 2016 Apr 4.</citation>
    <PMID>27058744</PMID>
  </reference>
  <reference>
    <citation>Hung CY, Hsiao MY, Chang KV, Han DS, Wang TG. Comparative effectiveness of dextrose prolotherapy versus control injections and exercise in the management of osteoarthritis pain: a systematic review and meta-analysis. J Pain Res. 2016 Oct 18;9:847-857. eCollection 2016.</citation>
    <PMID>27799816</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasanuddin University</investigator_affiliation>
    <investigator_full_name>Bumi Herman</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>COMP</keyword>
  <keyword>uCTX-II</keyword>
  <keyword>Prolotherapy</keyword>
  <keyword>Functional Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

